Logo image of ZJYL

JIN MEDICAL INTERNATIONAL LT (ZJYL) Stock Fundamental Analysis

NASDAQ:ZJYL - Nasdaq - KYG5140V1124 - Common Stock - Currency: USD

0.6996  +0.06 (+9.16%)

After market: 0.7184 +0.02 (+2.69%)

Fundamental Rating

4

ZJYL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of ZJYL get a neutral evaluation. Nothing too spectacular is happening here. ZJYL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ZJYL was profitable.
In the past year ZJYL has reported a negative cash flow from operations.
Each year in the past 5 years ZJYL has been profitable.
Of the past 5 years ZJYL 4 years had a positive operating cash flow.
ZJYL Yearly Net Income VS EBIT VS OCF VS FCFZJYL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

1.2 Ratios

The Return On Assets of ZJYL (8.03%) is better than 90.91% of its industry peers.
The Return On Equity of ZJYL (12.76%) is better than 89.30% of its industry peers.
With an excellent Return On Invested Capital value of 7.79%, ZJYL belongs to the best of the industry, outperforming 86.63% of the companies in the same industry.
ZJYL had an Average Return On Invested Capital over the past 3 years of 9.49%. This is in line with the industry average of 7.91%.
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROIC 7.79%
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ZJYL Yearly ROA, ROE, ROICZJYL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

ZJYL has a better Profit Margin (15.64%) than 93.05% of its industry peers.
ZJYL's Profit Margin has declined in the last couple of years.
ZJYL has a better Operating Margin (15.48%) than 85.56% of its industry peers.
In the last couple of years the Operating Margin of ZJYL has declined.
ZJYL has a Gross Margin of 40.43%. This is in the lower half of the industry: ZJYL underperforms 67.91% of its industry peers.
ZJYL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
ZJYL Yearly Profit, Operating, Gross MarginsZJYL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

ZJYL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ZJYL has been increased compared to 1 year ago.
ZJYL has less shares outstanding than it did 5 years ago.
ZJYL has a worse debt/assets ratio than last year.
ZJYL Yearly Shares OutstandingZJYL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ZJYL Yearly Total Debt VS Total AssetsZJYL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 5.68 indicates that ZJYL is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZJYL (5.68) is better than 79.68% of its industry peers.
ZJYL has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.39, ZJYL is in line with its industry, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 5.68
ROIC/WACC1.08
WACC7.22%
ZJYL Yearly LT Debt VS Equity VS FCFZJYL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 2.50 indicates that ZJYL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.50, ZJYL is in line with its industry, outperforming 47.59% of the companies in the same industry.
ZJYL has a Quick Ratio of 2.19. This indicates that ZJYL is financially healthy and has no problem in meeting its short term obligations.
ZJYL has a Quick ratio (2.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.19
ZJYL Yearly Current Assets VS Current LiabilitesZJYL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

ZJYL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.76%, which is quite good.
Measured over the past 5 years, ZJYL shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
The Revenue has grown by 18.57% in the past year. This is quite good.
The Revenue has been growing slightly by 2.90% on average over the past years.
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZJYL Yearly Revenue VS EstimatesZJYL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 34.98, which means the current valuation is very expensive for ZJYL.
Based on the Price/Earnings ratio, ZJYL is valued a bit cheaper than the industry average as 73.26% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.69, ZJYL is valued a bit more expensive.
Industry RankSector Rank
PE 34.98
Fwd PE N/A
ZJYL Price Earnings VS Forward Price EarningsZJYL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ZJYL is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.79
ZJYL Per share dataZJYL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

The decent profitability rating of ZJYL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)10.67
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZJYL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JIN MEDICAL INTERNATIONAL LT

NASDAQ:ZJYL (7/23/2025, 7:44:48 PM)

After market: 0.7184 +0.02 (+2.69%)

0.6996

+0.06 (+9.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.64%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap109.52M
AnalystsN/A
Price TargetN/A
Short Float %0.53%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 34.98
Fwd PE N/A
P/S 4.66
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.96
EV/EBITDA 13.79
EPS(TTM)0.02
EY2.86%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.15
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)10.67
Profitability
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROCE 12.7%
ROIC 7.79%
ROICexc 23.55%
ROICexgc 25.79%
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
FCFM N/A
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ROICexc(3y)22.47%
ROICexc(5y)22.7%
ROICexgc(3y)23.46%
ROICexgc(5y)23.49%
ROCE(3y)12.88%
ROCE(5y)15.84%
ROICexcg growth 3Y-2.39%
ROICexcg growth 5Y-7.19%
ROICexc growth 3Y-4.58%
ROICexc growth 5Y-8.54%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 2.84
Cap/Depr 324.82%
Cap/Sales 4.78%
Interest Coverage 15.2
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.19
Altman-Z 5.68
F-Score3
WACC7.22%
ROIC/WACC1.08
Cap/Depr(3y)128.78%
Cap/Depr(5y)88.37%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.9%
EBIT growth 3Y11.4%
EBIT growth 5Y-3.75%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-177.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.86%
OCF growth 3YN/A
OCF growth 5YN/A